Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Among people treated for hepatitis C, diabetes and chronic kidney disease were both linked to a higher risk of cardiovascular death.
This guide explains key aspects of today’s most effective hep C therapies
Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.
Premature discontinuation of hepatitis C treatment did not diminish the likelihood of sustained virological response.
Some state Medicaid programs and prison systems still restrict treatment based on substance use or stage of liver disease.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
A meta-analysis has helped clear up conflicting previous evidence regarding this association.
In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.
Newer hep C meds may give more prisoners access to the cure.
The good news is the latest meds wreak much less havoc on your crowning glory.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.